Search QAs

We have a question regarding S.37.01 Cell C0320 – Exemptions (included in the Implementing Regulation 2023/894), where we seek clarification of what information is asked for specifically. The cell C0320 makes reference to Article 187 in the delegated regulation, and in its reporting events, EIOPA has also referred to the banking regulation (Article 400 in the Regulation (EU) No 575/2013); We understand this is because both articles/legislations are referred to in the FICOD reporting requirements (Implementing Regulation 2022/2454, template FC.06, cell FC0270).

Is the column "Maximum cover by transaction" (C0150) meant to include only internal reinsurance?

We have read EIOPA’s answer in relation to question #2774, and would like to clarify our understanding in regards to the instructions provided to the template S.36.05 in EU/2023/894. In terms of the overlap mentioned between S.36.01/S.36.02 and S.36.05, is it correctly understood then that the instructions in the “General comments” to QRT S.36.05.01 (“This template shall report the P&L associated to all (significant, very significant and transactions required to be reported in all circumstances) intra-group transactions between entities in the scope of the group supervision or P&L transaction considered as significant or very significant intragroup transactions or transactions required to be reported in all circumstances”) should be read in the following manner:

Background and Request for Clarification – Market Concentration Risk under Solvency II
We are assessing the application of the Market Concentration Risk module under Solvency II for two insurance undertakings, A and B, both with total assets exposed to the Market Concentration Risk module amounting to EUR 100 million.

Taxonomy 2.8.0 introduced a identical data point between S.23.01.04.01 R0200/C0010 and S.23.04.04.11 R0040/C0861. In addition, the designation on S.23.0.04.01 R0200/C0010 has been changed from ‘Minority interests (if not reported as part of a specific own fund item)’ to ‘Minority interests at group level’.

Could you please provide me with information whether EIOPA has ever issued any statement or publication regarding the issue of demerger / spin-off of an (re)insurance undertaking?

When do you plan to publish results of the survey on European insurers on their use of generative AI? Did you do any previous studies or surveys on the use of gen AI in the field?

Since 1 January 2025, EIOPA has stopped publishing technical information for 11 non-EEA currencies. However in the Report on the calculation of the UFR for 2025, UFR values for these 11 currencies are provided, e.g. Malaysian Ringgit. In the equivalent report in 2026 and future years, will UFR values continue to be provided for these 11 non-EEA currencies?

It seems that the rules EV75-2 and EV52- are incompatible:
EV75-2: Issuer sector according to ESA 2010 should be reported for non-ISIN securities only.
--> BUSINESS(en) - [EV75-2];[isNull((t: SE.06.02.16.02, c: EC0231, z: Z0001, filter: matches([s2c_dim:UI], "^((ISIN/.*)|(CAU/ISIN/.*))")) reported as {$v1})]|
This states that the Issuer sector is not required if the asset identification is an official ISIN (no mention of CIC).